Tailored Anti-platelet Therapy After DES Implantation in High-risk Patients
Coronary Artery Disease
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring Coronary artery disease, antiplatelet therapy, platelet reactivity
Eligibility Criteria
Inclusion Criteria: Patients > 18 years old Patients who previously underwent percutaneous coronary intervention with drug-eluting stent implantation 12 months (± 3 months) ago. At least one high risk characteristics of ischemic events High risk patients Acute coronary syndrome Previous history of cerebrovascular accidents Previous history of peripheral artery intervention Heart failure Diabetes mellitus requiring medication Chronic kidney disease (regardless of requirement of renal replacement therapy) High risk lesions Left main disease Multivessel disease, 2- or 3- vessels Bifurcation lesions requiring 2 or more stents Chronic total occlusion In-stent restenosis Graft lesions Diffuse long lesion requiring stent(s) with total stent length ≥28 mm Lesion at small sized vessel requiring stent(s) with stent diameter ≤2.5 mm Calcified lesions requiring atherectomy Exclusion Criteria: Patients > 80 years old Pregnant women or women with potential childbearing Life expectancy < 1 year Refusal or inability to understand of informed consent Patients eligible to long-term anticoagulation therapy Patients with major bleeding events in previous 3 months before randomization
Sites / Locations
- Severance HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Uniform Therapy
Tailored Therapy
Patients will continue clopidogrel monotherapy for 24 months from randomization, irrespective of their PRU measurement.
Patients in the intervention arm will receive tailored anti-platelet therapy according to PRU and bleeding risk